Healthcare investment firm Vivo Capital has announced the final closing of its life science fund, Vivo Opportunity Fund, at an oversubscribed US$635 million, bringing the firm’s total funds under management to over US$2.2 billion. Investors of the fund includes undisclosed financial institutions, pension funds, endowments, foundations and family offices, the company said in a statement on Tuesday. The fund plans to invest the capital in small to mid-cap public life sciences companies through follow-on financing, private placements, initial public offerings …

Vivo Capital Closes Oversubscribed $635M Life Sciences Fund appeared first on China Money Network.